IP Library › Granted Patent US 11,344,358
Granted Patent B2
US 11,344,358 · App. 16/444,496 · Granted May 31, 2022

Apparatus for selective treatment of tissue

Inventors: Irina Erenburg (Milton, MA); Jayant Bhawalkar (Auburndale, MA); Charles Holland Dresser (Wayland, MA); Joseph Ting (Acton, MA)
Assignee: Avava, Inc.
A61B18/04A61K41/0028A61K41/0052A61N5/062A61B2018/00577A61N1/44A61N5/067A61N2005/0626
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,344,358
App. No.
16/444,496
Granted
May 31, 2022
Kind
B2
Abstract

A method includes depositing within a predetermined region of a target tissue with a plurality of dopant particles. The method also includes focusing a laser beam to a focal region that overlaps with at least a portion of the predetermined region. The focal region includes at least a first dopant particle of the plurality of dopant particles. The method further includes adjusting a first parameter of the laser beam to generate plasma within a plasma volume comprising the first dopant particle.

Claims (21)

1. A method comprising:

depositing within a predetermined region of a target tissue with a plurality of dopant particles;

focusing a laser beam to a focal region that overlaps with at least a portion of the predetermined region, wherein the focal region includes at least a first dopant particle of the plurality of dopant particles;

adjusting a first parameter of the laser beam comprising at least a maximum intensity to generate plasma within a plasma volume comprising the first dopant particle, wherein the maximum intensity is between a threshold value of the target tissue without the dopant particles and a threshold value of the target tissue with the dopant particles; and

scanning the focal region of the laser beam along a first path in the predetermined region;

wherein scanning the focal region along the first path is configured to one or more of destroy, obliterate, cavitate, ablate, denature, and devitalize the target issue along the first path.

2. The method of claim 1 , wherein the plasma is generated within the first dopant particle.

3. The method of claim 1 , wherein the plasma is generated in the plasma volume via laser induced thermal breakdown (LITB) due to absorption of a portion of the laser beam by the first dopant particle.

4. The method of claim 3 , wherein the maximum intensity of the laser beam in the focal region is below a LITB threshold value of the target tissue without the dopant particles.

5. The method of claim 4 , wherein adjusting the first parameter of the laser beam comprises setting the maximum intensity of the laser beam to a value between the LITB threshold value of the target tissue without the dopant particles and the LITB threshold value of the target tissue with the dopant particles.

6. The method of claim 1 , wherein the plasma is generated in the plasma volume via laser induced optical breakdown (LIOB) due to absorption of a portion of the laser beam by the first dopant particle.

7. The method of claim 6 , wherein the maximum intensity of the laser beam in the focal region is below a LITB threshold value of the target tissue without the dopant particles.

8. The method of claim 7 , wherein adjusting the first parameter of the laser beam comprises setting the maximum intensity of the laser beam to a value between the LITB threshold value of the target tissue without the dopant particles and the LITB threshold value of the target tissue with the dopant particles.

9. The method of claim 1 , wherein adjusting the first parameter of the laser beam comprises adjusting one or more of a power, a pulse energy, and a wavelength of the laser beam.

10. The method of claim 1 , wherein the plurality of dopant particle includes one or more of sodium chloride, silicon, silver nanoparticles, metal nanocomposites, dendritic molecules.

11. The method of claim 1 , wherein the generated plasma includes a first plasma generated from the first dopant particle, and a second plasma generated from the target tissue.

12. The method of claim 1 , wherein the plurality of dopant particle are deposited in the predetermined region by at least injecting the plurality of dopant particles in the target tissue.

13. The method of claim 1 , wherein the laser beam is focused by a lens having a numerical aperture of at least 0.3.

14. The method of claim 1 , wherein the laser beam has a wavelength selected based upon at least one of scattering and absorption in the target tissue.

15. The method of claim 14 , wherein the wavelength is between 0.5 and 2.0 micron.

16. The method of claim 1 , wherein the plurality dopant particles are nanoparticles.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2024
From: AVAVA, INC.
To: ANKURA TRUST COMPANY, LLC
Reel/Frame 066181/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2019
From: ERENBURG, IRINA; BHAWALKAR, JAYANT; DRESSER, CHARLES HOLLAND; TING, JOSEPH
To: AVAVA, INC.
Reel/Frame 050623/0580 →
Continuity (2)
Provisional Application 62688855 · Jun 22, 2018
Related Publication 20190388134A1 · Dec 26, 2019